Blocking a key protein that enables ovarian cancer has shown promise in the fight against it. But a three-pronged approach including chemotherapy and immunotherapy appears to be even more effective, ...
Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that cancer turns the body's defenses against itself. However, new research from Nagoya University published in ...
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that the cancer turns the body’s defenses against itself. However, new research from Nagoya University ...
Early mortality in epithelial ovarian cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that the cancer turns the body's defenses against itself. However, new research from Nagoya University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results